Liposome Technology Inc. on Thursday said it has filed for a 3million-share stock offering. If the offering is completed, theMenlo Park, Calif., company will have 16 million sharesoutstanding.

LTIZ is developing liposome and lipid-based products to treatinfectious diseases and cancer. The company has two productsin Phase II clinical trials: Amphocil liposomal amphotericin Banti-fungal drug and a bronchodilator inhaled liposomalalbuterol product.

Underwriters Oppenheimer & Co. Inc. and Kidder, Peabody & Co.Inc. have an option to buy an additional 450,000 shares tocover overallotments. The stock (NASDAQ:LTIZ) closed up 50cents at $10 on Thursday.

(c) 1997 American Health Consultants. All rights reserved.